We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 16, 2021

Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

American Journal of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma: Final Results From the MCRN-003/MYX.1 Single Arm Phase II Trial
Am. J. Hematol 2021 Mar 01;[EPub Ahead of Print], CP Venner, R LeBlanc, I Sandhu, D White, AR Belch, DE Reece, C Chen, S Dolan, M Lalancette, M Louzada, A Kew, A McCurdy, B Monteith, T Reiman, G McDonald, M Sherry, E Gul, BE Chen, AE Hay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading